BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children | MicrobiomeTrials← Back to trialsNCT07893444
BRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-08Est. Completion: 2027-11-30
Enrollment target: 90 participants Locations- Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province, Fuzhou, Fujian, China
- Guangzhou Chest Hospital, Guangzhou, Guangdong, China
- Guiyang Public Health Clinical Center, Guiyang, Guizhou, China
- Third People's Hospital of Liupanshui, Liupanshui, Guizhou, China
- Zunyi Infectious Diseases Hospital, Zunyi, Guizhou, China
- The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China
- Ganzhou Fifth People's Hospital, Ganzhou, Jiangxi, China
- The Fourth People's Hospital of Qinghai Province, Xining, Qinghai, China
- Shandong Public Health Clinical Center, Jinan, Shandong, China
- Huashan Hospital, Shanghai, Shanghai Municipality, China
- The First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang Uygur Autonomous Region, China
- Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China
- The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Other microbiome trials you might be interested in
Mycobacterium InfectionsTuberculosis, Multidrug-ResistantLatent TuberculosisTuberculosisExtensively Drug-Resistant Tuberculosis
Background:
\- Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are inter…
Bethesda, United States
Rifampicin-Resistant Pulmonary TuberculosisMultidrug-Resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tol…
Beijing, ChinaEst. completion Sep 29, 2028
Non-small Cell Lung Cancer
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United StatesEst. completion Jan 24, 2028